搜索

quanfu quanfu

Product Center

Homepage
/
News
/
Company news
/
Successfully Selected as a National Open Research Project!

Successfully Selected as a National Open Research Project!

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2023-11-15
  • Views:

(Summary description)Recently, after evaluation by experts from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), Ab&B Bio Tech Co., Ltd. JS's research project titled "Post-Marketing Safety Evaluation of Tetravalent Influenza Virus Subunit Vaccines" has been successfully selected as a national open research project.

Successfully Selected as a National Open Research Project!

(Summary description)Recently, after evaluation by experts from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), Ab&B Bio Tech Co., Ltd. JS's research project titled "Post-Marketing Safety Evaluation of Tetravalent Influenza Virus Subunit Vaccines" has been successfully selected as a national open research project.

  • Categories:Company news
  • Author:
  • Origin:
  • Time of issue:2023-11-15 15:17
  • Views:
Information
Recently, after evaluation by experts from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA), Ab&B Bio Tech Co., Ltd. JS's research project titled "Post-Marketing Safety Evaluation of Tetravalent Influenza Virus Subunit Vaccines" has been successfully selected as a national open research project.
 
 
The project was led by Mr. Tao Hang, Head of Drug Vigilance and Director of Medical Marketing at Ab&B Bio Tech Co., Ltd. JS. Under the guidance of the Jiangsu Provincial Center for Adverse Drug Reaction Monitoring and other institutions, it was completed in collaboration with multiple organizations, including the Jiangsu Provincial Center for Adverse Drug Reaction Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, and Nanjing Medical University.
The project aims to evaluate the safety of the quadrivalent influenza virus subunit vaccine in a large population aged 3 years and above, explore innovative methods for post-marketing dynamic safety monitoring of vaccines, utilize large-scale digital data collection to develop surveillance models tailored to China's national conditions for newly launched drugs, and support the advancement of China's vaccine regulatory system toward higher maturity goals.
Scan the QR code to read on your phone
Previous: Kickoff Meeting for Phase I Clinical Trial of Freeze-Dried Human Rabies Vaccine (Human Diploid Cells) Successfully Held
Next: Ab&B Bio-Tech Co., Ltd. JS Delegation Conducts Multinational Exchange and Cooperation Activities in Brazil, Uruguay, Chile, and Spain
Previous: Kickoff Meeting for Phase I Clinical Trial of Freeze-Dried Human Rabies Vaccine (Human Diploid Cells) Successfully Held
Next: Ab&B Bio-Tech Co., Ltd. JS Delegation Conducts Multinational Exchange and Cooperation Activities in Brazil, Uruguay, Chile, and Spain

Relevant information

Got a project? Contact us today !

At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.

Contact

E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City

Quick view

Follow us

Copyright © 2022 Ab&B Bio-Tech CO.,LTD.JS All Rights Reserved.   Powered by:www.300.cn
Verification 苏ICP备16005775号-1
Search